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-AbstractSynthetic strategies to combat antibiotic resistance
By
Jonathan Fifer
University of New Hampshire, December 2018

The design and synthesis of β-lactamase inhibitors is a constant area of study to overcome
the growing problem of resistance to β-lactam antibiotics. Serine dependent β-lactamase enzymes,
through a hydrolysis mechanism, can deactivate many traditional β-lactam antibiotics. Designing
drugs to specifically target β-lactamases is of great interest because such drugs could be used in
tandem with traditional β-lactam antibiotics. Aza-β-lactam molecules have been theorized to be
less vulnerable to hydrolysis than the traditional β-lactams. Nucleophilic attack of the active-site
serine of the β-lactamase on the aza-β-lactam ring would lead to a carbamoyl-enzyme intermediate,
which would be partially stabilized due to the neighboring nitrogen atom and thus is expected to
be more hydrolytically stable than the corresponding acyl-enzyme intermediate of a β-lactam.
The initial attempt to synthesize the aza-carbacepham 1 utilized a rhodium catalyzed N-H
insertion as the key step to form the substituted piperidine ring fused to the aza-β-lactam ring.
With the use of aldehyde 8, a Wittig reaction was conducted to extend the carbon chain, but
problems arose with the removal of the N-acetyl group. Multiple pathways were attempted but all

xii

were unsuccessful in cleaving the N-acetyl group, so a different synthetic approach was explored
that utilized an aldol reaction to form the respective ring.
The synthesis of aza-carbapenam 33 originally proceeded via enol-ether 34a/b followed
by acid catalyzed conversion to the corresponding alcohol 35. But due to low yields, a different
approach involving hydroboration of alkene 47 was explored. With the use of a model system, the
Wittig conditions were optimized and applied to aldehyde 8 to form alkene 47. Traditional
hydroboration conditions were then attempted with the formation of unexpected product 48.
Rapamycin has been found to potentiate oxacillin activity against several strains of
methicillin-resistant Staphylococcus aureus (MRSA), but its mechanism of action is unknown.
The interaction of rapamycin with oxacillin and MRSA are going to be studied with a photoaffinity
labeling process. Diazirine linker 49 was synthesized and initial steps to alkylate rapamycin were
attempted. NMR data of rapa-linker 50 is still inconclusive due to low isolated yields.

xiii

-Chapter 1-IntroductionThe β-lactam antibiotic penicillin was discovered in 1928 by Alexander Fleming.1 The
full potential of penicillin was not understood until the 1940s, when the era of antibiotics truly
began as the demand for medication increased drastically. With the demand for large-scale
production due to World War II, penicillin became one of the first antibiotics on the market.2 The
effectiveness of penicillin then brought on the discovery of other compounds that had similar
bacterial properties. Chemists were eager to apply the antibiotic properties of the β-lactam ring of
penicillin and began extensively researching natural product isolation and synthesis. The β-lactam
nucleus, 6-aminopenicillanic acid, was discovered to be crucial when synthesizing and modifying
penicillin.3 Cephalosporin C was isolated from a strain of Cephalosporium acremonium, and this
brought on an entirely new family in the β-lactams.3 The β-lactam family includes penicillins,
cephalosporins, carbapenems, and monobactams represented below in Figure 1.4

Figure 1. The four common classes of β-lactam antibiotics used in the clinic.

1

The β-lactams have been a powerful tool as a treatment for bacterial infections leading
them to become a commonly prescribed class of antibiotics. The antibacterial property comes
from the peptide mimic; penicillin mimics a component of the cell wall which allows it to bind to
an enzyme that constructs and strengthens the cell wall.5,6

A penicillin-derived entity is

irreversibly bound by the transpeptidase and carboxypeptidase enzymes essential for bacterial cell
wall synthesis. These biosynthetic enzymes are obvious therapeutic targets leading to inhibition
of the peptidoglycan cross-linking transpeptidase that cleaves the peptidoglycan D-Ala-D-Ala
terminus in the serine acylation half-reaction.5,6 With loss of the terminal D-Ala, a cross-link is
formed in the deacylation half-reaction. Should this enzyme bind a substrate mimic, the initial
acylation reaction remains unaffected, but the deacylation mechanism is abolished, the enzyme
will fail to complete cell wall synthesis.5,6
With the synthesis halted, the cell wall loses its integrity leading to bacterial cell death. 5,6
The crystal structures of these enzymes have been studied to identify the enzyme active sites and
determine which interactions are essential to the high binding affinity of β-lactam antibiotics.7
Due to extensive overuse and misuse, bacteria have developed mechanisms of defense against the
β-lactam antibiotics. Only a few years after penicillin was used clinically, reports of penicillinresistant Staphylococcus aureus emerged.8 This was mainly due to the expression of β-lactamase
enzymes. These enzymes hydrolyze the β-lactam ring eliminating the drug’s antibacterial activity.
The β-lactamase enzymes are divided into classes A, B, C, and D. Classes A, C, and D
utilize an active site serine to initiate β-lactam hydrolysis (Scheme 1).9 Each follow a similar
mechanism of hydrolysis, but differ in the catalytic residue to hydrolyzes the β-lactam ring. Class
C utilizes a lysine-tyrosine pair for the catalytic residue, compared with class D, which is activated
by a carboxylated-lysine.10,11
2

Scheme 1. The hydrolysis of a β-lactam by a serine-β-lactamase.
With class D, a serine nucleophile attacks the lactam carbonyl yielding a covalent acylenzyme intermediate.

The tetrahedral oxyanion intermediate for this acylation reaction is

stabilized by two main-chain amides and electrostatically by a second active-site lysine. The ester
linkage is then hydrolyzed by attack of the α face of the ester by an active-site water affording an
inactivated β-lactam.11 Much progress has been made in attempts to prevent the hydrolysis of the
acyl-enzyme intermediate, but more distinct enzyme types continue to be discovered. As of 2017,
the Comprehensive Antibiotic Resistance Database (CARD) lists over 1200 different serine-βlactamase enzymes.12
Class B β-lactamases employ one or two Zn2+ ions to hydrolyze the β-lactam antibiotic
(Scheme 2).13 The role of the Zn2+ ions is to catalytically activate the hydrolytic water to open the
β-lactam ring, and simultaneously stabilize the reaction intermediates.14 Metallo-β-lactamases
have been viewed as less of a threat due to their more geographically localized outbreaks of the
enzyme, but the enzyme’s molecular epidemiology is changing.13 This change is driven by the
emergence of mobile genetic elements containing metallo-β-lactamase genes that are now
frequently found in Gram-negative pathogens including Enterobacteriaceae, Pseudomonas, and
Acinetobacter species across the globe.15,16

3

Scheme 2. Mechanism of metallo-β-lactamase catalyzed hydrolysis of β-lactam antibiotic.
In 1959 various penicillin analogues such as methicillin were developed in attempts to
sterically protect the β-lactam ring.17

Shortly after methicillin was brought to the market,

methicillin-resistant Staphylococcus aureus (MRSA) isolates were detected.18 The increased
resistance to methicillin was due to alterations of the β-lactamase enzyme that resulted in a lower
affinity for the β-lactam.19 The restriction to the active site made treatment of the bacteria difficult,
and the growing emergence of MRSA identified a need for new treatment options.
Cephalosporins were discovered in the late 1940s, and were found to be less susceptible to
deactivation by staphylococcal β-lactamase.8 Early variations of cephalosporins were found to be
active against staphylococci, but were found to be even more beneficial against gram-negative
organisms such as Pseudomonas aeruginosa.17 Carbapenems and monobactams, discovered in
1985, were found to be useful against bacteria typically unaffected by other β-lactam.20

4

Carbapenems have been reserved for treatment of the most difficult bacterial infections, however,
resistance to them has become more widespread due to the increased prevalence of
carbapenemases.8 Carbapenemases represent the most versatile family of β-lactamases, with an
extensive spectrum of β-lactam-hydrolyzing enzymes. Although known as “carbapenemases,”
many of these enzymes recognize almost all hydrolyzable β-lactams, and most are resilient against
inhibition by many commercially available β-lactamase inhibitors.21
The current methods to combat β-lactam resistance include: designing new β-lactam
antibiotics that are less susceptible to hydrolysis, or designing new β-lactamase inhibitors to
prevent β-lactam hydrolysis.8 Designing new β-lactam antibiotics is an ongoing process, but the
production of β-lactamase inhibitors has been more successful. In 1972 clavulanic acid was found
to have limited antibiotic activity despite the β-lactam ring (Figure 2), however it shows a high
affinity for β-lactamase enzymes.22 In 1984, Augmentin, which contains clavulanic acid and
amoxicillin, became the first β-lactam/β-lactamase inhibitor antibiotic and in 2001 Augmentin
became the best-selling antibiotic on the market.8
With much work being done to find potential inhibitors of β-lactamases,
diazabicyclooctanes have shown promising results.23 Mimics of β-lactams, such as Avibactam
(Figure 2), have been found to have activity against class A, C, and D β-lactamase.24 This is due
to the unique carbamoyl acyl-enzyme intermediate that does not decompose by a hydrolytic
mechanism.25

In its place, the decarbamylation occurs by a recyclization of the

diazabicyclooctanes fused ring to reform the inhibitor to then inactivate more serine-β-lactamase.25
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Figure 2. Structure of Avibactam and Clavulanic acid.
Bicyclic imidazolidinones represented in Figure 3, are found to also have interesting
inhibition ability.26 When tested, low antimicrobial activity was observed against bacteria for
imidazolidinones A, B, C, and D from figure 3.26,27

Figure 3. Examples of β-lactam mimics with a bicyclic imidazolidinone framework.
Chandrakala et al. explored a synthetic route to make 1,3-diazetidin-2-ones (aza-β-lactams)
and proposed that the aza-β-lactam could theoretically have high inhibition ability against βlactamases.26 The process begins with the nucleophilic attack of the serine β-lactamase on the
non-traditional β-lactam ring, which leads to a carbamoyl-enzyme intermediate that is partially
stabilized due to the neighboring nitrogen atom. The carbamate acyl-enzyme intermediate is
expected to be more hydrolytically stable than the corresponding ester acyl-enzyme intermediate
of a β-lactam (Scheme 3).
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Scheme 3. Resonance stabilization of the acyl-enzyme intermediate of an aza-β-lactam with a βlactamase compared to a traditional β-lactam with a β-lactamase.
In the more traditional β-lactam structure, extra stabilization is not present because the
enzyme attacks the β-lactam ring and forms a corresponding ester that can readily be hydrolyzed
to leave the β-lactam deactivated. With growing resistance due to serine-β-lactamases and
metallo-β-lactamases, new treatment options are of great interest. The aza-β-lactam analogues are
close structural mimics of β-lactams and also benefit from resonance stabilization in the acylenzyme intermediate. Aza-β-lactam structures have not been examined for activity against βlactamases, so an efficient synthetic route is required to synthesize a library of derivatives.

7

-Results and DiscussionThe Johnson research group at University of New Hampshire conducted computational
studies to determine whether or not several different acyl-enzyme intermediates were less
susceptible to hydrolysis than an ester.28 The C6 position of the β-lactam was substituted with
different heteroatoms, which would form an acyl-enzyme ring linkage.28 The C6 position was
substituted with nitrogen, oxygen, and a sulfur to study the different strengths of the respective
acyl-enzyme intermediate (Figure 4).

Figure 4. Structures explored computationally for the relative strength of the acyl-enzyme
linkage.
The potential energy surface of the methanol-assisted hydrolysis of the acyl-enzyme
intermediate was compared for each substituted variation. Based on the computational results, all
derivatives have a carbamate acyl-enzyme linkage that is less susceptible to hydrolysis compared
to the ester of the typical β-lactam (X= CH2), except for the oxalactam derivative.28 The data also
suggest that the N-acetyl aza-β-lactam would be the most reasonable to form acyl-enzyme
intermediate that is less susceptible to the methanol-assisted hydrolysis.28

With promising
8

computational data, investigation to efficiently synthesize various aza-β-lactam derivatives was
explored.
In order to test the aza-β-lactam compounds for inhibitory activity against β-lactamases, a
simple and efficient synthetic pathway is needed. Ideally the pathway would utilize the same
chemistry but have minor variations to produce multiple derivatives. The first compound of
interest was an aza-carbacepham (Figure 5, 1). After a general synthetic pathway is determined,
the phenyl ring will be functionalized with an electron withdrawing or donating group. Due to the
conjugation of the structure, the addition of select groups could change the electronics of the azaβ-lactam ring, which may affect the acylation or deacylation rates during the reaction with βlactamases.
The initial pathway utilized a rhodium-catalyzed N-H insertion for the formation of the
respective ring attached to the aza-β-lactam ring (Scheme 4).29 The proposed method would
require minimal steps that utilized mild reaction conditions to efficiently synthesize azacarbacepham 1 in Figure 5.

Figure 5. The target molecules of the aza-carbacepham 1-4.
The synthetic pathway began with the formation of pyrimidin-2-one 6 from phenyl urea 5
and acetylacetone.30 Compound 6 was then exposed to photochemical conditions to form the
respective aza-β-lactam ring in 7, initially with a low yield of 27%.26
9

Scheme 4. Initial synthetic steps to form aza-carbacepham 1 utilizing a Rh catalyzed N-H
insertion.
To combat the low yield, flow chemistry was used to optimize the photochemical 4π
electrocyclization. Flow chemistry is useful to the synthetic chemist because of such advantages
as reduced reaction times, increased heat management, increased product purity and atom
efficiency.31 The high surface-to-volume ratio allows for more efficient mixing and photoreactive
conversion, and the use of automated systems allow continuous production of compounds with
high efficiency. For the photochemical 4π electrocyclization of 6 to 7, the initial concern with the
10

photochemical reaction was the heat generated by the photoreactor, which from long reaction times
might promote the reverse reaction. A simple photo-flow-reactor was constructed in attempts to
minimize this issue. Polytetrafluoroethylene (PTFE) tubing was coiled around a large glass tube
that had the ability to be cooled. The reaction mixture could then flow through the coil with the
use of a syringe pump. With this design, various flow rates could be used to allow for longer
reaction times and still minimize the heat generated in the solution. The reaction was monitored
by 1H NMR, and the conversion ratio of starting material 6 to product 7 was observed (Table 1).
The flow rate was varied to determine how the reaction times affect the percent conversion
(Table 1). By decreasing the flow rate and thus increasing the reaction time, the starting material
is given more exposure to the radiated light, which increases the efficiency of the reaction.
Decreasing the flow rate from 0.322 mL/min (30 minutes) to 0.161 mL/min (60 minutes) results
in a large increase in product formation. Varying the concentration was next investigated. The
original concentration of 0.016 M was increased to 0.032 M and 0.048 M; with the increase in
concentration, a decrease in product formation was observed (Table 1). This is likely due to the
low solubility of 6 in benzene. The syringe pump had a difficult time pushing the solution through
the reactor. As the solution was pushed through the photo-reactor, solid would form on the syringe
preventing the consistent flow of the syringe pump.

11

Table 1. Optimization of 4π electrocyclization using flow chemistry.
Concentration
(M)
0.016

Time
(min)
30

Flow rate
(mL/min)
0.322

Temperature
(οC)
0

% Conversion
of 6 to 7
21

0.016

60

0.161

0

44

0.032

30

0.322

0

23

0.032

60

0.161

0

36

0.048

30

0.322

0

15

0048

60

0.161

0

32

0.016

30

0.322

rt

33

0.016

120

0.080

rt

92

0.016

150

0.060

rt

95

Cooling the reaction mixture was examined to determine if it was necessary. When the
reaction was conducted at room temperature, an increase in the conversion of 6 to 7 from 21% to
33% was observed. Nishio et al., also reported that longer reaction times dramatically increase
the overall conversion of pyrimidin-2-one to the corresponding diazabicyclo-ene.32 Much slower
flow rates were used, 0.080 mL/min (120 min) and 0.060 mL/min (150 min), to yield 92% and
95% conversion, respectively. Unfortunately, with large scale reaction mixtures and long reaction
times, a side product was observed by thin-layer chromatography (TLC). Due to the alkene on the
newly formed ring, an additional cyclization occurred causing an oligomer to form when examined
my NMR. The formation of the oligomer decreased the isolated yield of 7, but the increase from
20% to 68% is a respectable gain in yield.
The oxidative cleavage of alkene 7 to form the corresponding aldehyde 8 was first explored
using a modified procedure from Inoue et al.33,34 Osmium tetroxide (OsO4) was used in a 1:1
stoichiometric ratio to convert the alkene to a diol, which could be converted to the respective
12

aldehyde with the use of sodium periodate (NaIO4), (Scheme 5). When this was attempted with
7, no product formation was observed.33 In a different attempt, OsO4 was used catalytically with
N-methylmorpholine N-oxide (NMO) as co-oxidant (Scheme 5).34 Unfortunately, no product
formation was observed again. It was hypothesized that the second nitrogen atom adjacent to the
alkene may interfere with the reaction outcome, so a more direct approach was examined.
Compound 7 was subjected to ozonolysis and a reductive workup with dimethyl sulfide to form
aldehyde 8 in 60% yield.26

Scheme 5. Oxidative cleavage of 7 with OsO4 and NaIO4 to form aldehyde 8.
With the formation of aldehyde 8, a Wittig reaction was used to extend the carbon chain to
the required length for later cyclization. Phosphonium salt 9 was easily synthesized in one step by
reacting triphenylphosphine with ethyl-4-bromobutyrate.35 Phosphonium salt 9 was deprotonated
in situ with NaHMDS, and the resulting phosphorane was allowed to react with 8 to form 10.26,35
The low yield was due to a difficult isolation; multiple attempts afforded only a small amount of
pure product 10. The Wittig product 10 was easily hydrogenated with Pd/C to form 11.26
Regrettably, this brought up an issue with the current synthetic pathway; the N-acetyl group needed
to be removed without reducing the ester on the end of the carbon chain.
Various reducing techniques were explored in an attempt to selectively remove the Nacetyl group. The first approach utilized the Corey-Chaykovsky reaction conditions (Scheme 4).36
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Under these conditions, a sulfur ylide is typically formed that can convert carbonyl compounds
such as ketones to their corresponding epoxides. Chandrakala et al. observed that when Me3SI is
used to convert aldehyde 8 to an epoxide, simultaneous cleavage of the N-acetyl group occurs.26
When 11 was subjected to these conditions, removal of the N-acetyl group was not observed. A
modified procedure from Alessandro et al. was attempted, which utilized n-BuLi in THF for more
efficient generation of the sulfur ylide.37 Even under these conditions, removal of the N-acetyl
was not observed. Aldehyde 8 was also subjected to the Corey-Chaykovsky conditions in attempts
to reproduce the work of Chandrakala et al.; interestly no epoxide formation was observed.
Other reducing agents were also explored to remove the N-acetyl group from compound
11 (Scheme 6), lithium tri-tert-butoxyaluminum hydride and borane tetrahydrofuran complex were
found to be unsuccessful.38 A new strategy was examined: removal of the acetyl group before the
carbon chain is extended.

Scheme 6. Different reductive methods explored to remove N-acetyl group.
Chandrakala et al. observed that a strong reducing agent such as LiAlH4 is able to reduce
the aldehyde to the alcohol and simultaneously cleave the N-acetyl group.26 More mild reducing
agents, such as NaBH4, reduced the corresponding aldehyde but do not remove the N-acetyl.26
With a modified procedure from Dess et al., a DMP oxidation was attempted to oxidize alcohol
16 to aldehyde 17 (Scheme 7).39 Aldehyde 8 was reduced with LiAlH4 to form alcohol 16, this
was then subjected a DMP oxidation in attempt to form 17. NMR analysis of the crude sample
14

indicated a small amount of aldehyde formation, but it was unable to be isolated. Another common
oxidizing agent , PCC, was used but unfortunately no product formation was observed by TLC,
the hindered environment of the alcohol could have prevented the reaction from occurring.26 With
removal of the N-acetyl group being problematic and the Wittig reaction of 10 being very low
yielding, a different synthetic strategy was explored. The new route used an N-alkylated aldol ring
closure to form aza-carbacepham 1 (Scheme 8).26

Scheme 7. Early removal of N-acetyl with LiAlH4 prior to Wittig reaction.
Treatment

of

aldehyde

8

with

the

phosphorane

derived

from

(carbethoxymethyl)triphenylphosphonium bromide formed the Wittig product 18, which was
followed by catalytic hydrogenation of the alkene to produce 19.26,40 LiAlH4 was used to reduce
the ester to the corresponding alcohol 20 and concurrently cleave the N-acetyl group.26,40 The
initial isolated yield was low, therefore the reaction was then cooled to -10 οC in attempt to slow
down the rate and diminish the harshness of the reaction conditions. Cooling the reaction more
showed a slight increase in yield. The molar equivalents were also reduced from a 3:1 to 1:1 ratio
of LiAlH4 to 19, the corresponding yield was increased to 49%.
A tert-butyldimethylsilyl (TBDMS) protecting group was selected for its ability to
withstand basic conditions. tert-Butyldimethylsilyl chloride (TBDMSCl) was used to protect the
primary alcohol of 20 to yield TBDMS ether 21.26,40 The primary alcohol was protected to allow
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for the nitrogen atom to be alkylated. NaH was used to deprotonate the N-H, which was followed
by the addition of ethyl bromoacetate to yield N-alkylated TBDMS ether 22.26,40

Scheme 8. New synthetic pathway to reach aza-carbacepham 1 through a N-alkylated Aldol ring
closure.
The deprotection of 22 was attempted with tetra-n-butylammonium fluoride (Bu4NF) and
was found to be low yielding.26,40 The initial attempt at the deprotection gave alcohol 23 in a 62%
yield.26,40 Unfortunately, scaling up the reaction diminished the yield to <10%. It was observed
16

that the compounds in the reaction undergo degradation when the stoichiometric ratio of Bu4NF
to 22 is high. The initial attempt used a 2:1 ratio of Bu4NF to 22, and after 30 min one additional
equivalent of Bu4NF was added until all of 22 was consumed. In attempts to diminish degradation,
the molar equivalents were dropped to a 1:1 ratio. Unfortunately, lowering the molar equivalents
lengthened the reaction time, 1 h to 3 h, before the disappearance of starting material was observed.
After purification, very little alcohol 23 was isolated. In attempts to slow down degradation, the
solution was cooled to -10 οC. The reduced temperatures resulted in decreased degradation, but
the reaction yield was still very low.
Karimi et al. reported that N-iodosuccinimide (NIS) in methanol is a gentle and efficient
means to remove TBDMS protecting groups with subsequent easy purification.41 When this was
attempted with TBDMS ether 22, the reaction was monitored by TLC and no change was observed
(Scheme 9). Karimi et al. used simple alkyl chains with minimal functional groups for the study.
The various functional groups of 22 could have prevented any reaction from occurring.

Scheme 9. Attempted TBDMS removal with NIS.
The small quantity of alcohol 23 obtained was nonetheless carried through the pathway to
synthesize the final compound. The primary alcohol was oxidized to the corresponding aldehyde
with the use of PCC to form aldehyde 24.26 With the use of NaH, an aldol cyclization was used to
form 25.26 With the formation of 25, the final deprotection to convert the ethyl ester to the
corresponding acid was next explored. 25 was not used due to the small amount recovered from
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purification, ~2 mg. Instead 18 was used due to the convenience of synthesizing the compound in
minimal steps.
Two methods were explored, a basic and an acidic approach (Scheme 10). Koshikari et al.
explored hydrolysis of esters under organic solvent-free conditions.42 From a modified procedure,
18 was subjected to deprotection with LiOH in a methanol/water solution. No change was
observed when monitored by TLC, and starting material was recovered. The reaction was
attempted again with a 16 h reaction time, and once again no change was observed by TLC.
It has been reported that concentrated HCl in a dioxane/water/THF solution can convert
ethyl esters to the respective acids in moderate yields.43 When these conditions were applied to
18, some promising results were detected by NMR (Scheme 10). The NMR spectrum of the crude
sample indicated the disappearance of the ethyl group of the ester and the presence of the acid
proton. But after purification, no isolated compound was identified as 26. Furthermore, without
isolating the product, it was difficult to determine if acid 26 had formed. The same reaction
conditions were applied again with a longer reaction time of 16 h, but degradation was observed.
The same conditions were applied in a microwave reactor. The reaction was run for 30 min at the
temperature of 100 οC, but unfortunately the solution turned black and degradation was observed.

Scheme 10. Attempted ethyl ester deprotection to form corresponding acid under basic or acidic
conditions.
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Utilizing the optimized steps from Scheme 6, initial steps to form the p-fluorophenyl azacarbacepham 2 were completed (Scheme 11).

With the use of 4-fluorophenylurea 27, the

formation of the pyrimidin-2-one 28 was achieved with the same conditions as previously stated.
A flow rate of 0.080 mL/min (120 min) was applied to the photo-flow-reactor to generate 29,
which was subjected to ozonolysis and reductive workup to form aldehyde 30. With the use of
(carbethoxymethyl)triphenylphosphonium bromide under strongly basic conditions, the Wittig
product 31 was isolated and then hydrogenated in the presence of catalytic Pd/C to make ester 32.
Due to time restraints, the synthesis was stopped at this point. It was observed that the fluoro
substituent on the phenyl ring had little effect on the chemistry. Future steps of this study will
continue the synthesis forward with p-fluorophenyl aza-carbacepham 2 and apply the same
conditions to synthesize p-methoxyphenyl aza-carbacepham 3 and m-fluorophenyl azacarbacepham 4.

Scheme 11. Synthetic steps performed to synthesize the p-fluorophenyl aza-carbacepham 2.
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Other derivatives with the aza-β-lactam ring were also attempted, such as aza-carbapenam
33, the structure of which bears resemblance to the carbapenem class of β-lactam antibiotics
(Figure 6). It was hypothesized that much of the same chemistry described in Scheme 8 could be
utilized to synthesize aza-carbapenam 33 (Scheme 12).

Figure 6. Proposed target molecule aza-carbapenam 33.
Starting from aldehyde 8, multiple pathways were explored to homologate the alkyl chain.
The formation of alcohol 35 was found to be very difficult. In attempt to synthesize azacarbapenam 33, formation of an enol-ether followed by acidic conversion to an alcohol was
explored using a modified procedure from Zaytsev et al.44 The reaction was performed using
(methoxymethyl)triphenylphosphonium chloride under strongly basic conditions in a Wittig
reaction to form 4.3:1 mixture of E- and Z-enol ethers 34a and 34b, respectively (Scheme 12).
Unfortunately, isolated yields were low so future exploration of conditions was disregarded. The
acidic hydrolysis to form 35 was still attempted but was found to be inconclusive due to the small
scale of the reaction.
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Scheme 12. Theorized synthetic pathway to form aza-carbapenam 33.
Hydroboration was explored as another potential method to make alcohol 35 (Scheme 15).
Utilizing a modified procedure from Della Sala et al., methyltriphenylphosphonium bromide under
strongly basic conditions was used in a Wittig reaction.45 The resulting alkene was then subjected
to standard hydroboration conditions to generate the respective alcohol.45,46 The conditions were
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applied to aza-aldehyde 8 and the isolated yield was 9%. Because of the low yield, a sterically
hindered aldehyde was used in a model system to optimize the conditions.
For the model system (Scheme 13), a modified procedure was used from Bonneau et al.47
With the use of methyl 2-phenylacetate, two consecutive methylations were completed to yield
43.47 LiAlH4 reduction was used to produce the alcohol 44 followed by a PCC oxidation to make
the corresponding aldehyde 45.44 With the use of 45, various bases and temperatures were
examined to optimize the Wittig reaction for the formation of the hydroboration precursor.

Scheme 13. Synthetic pathway to make hindered aldehyde 45 for hydroboration model system.
Model system conditions were explored to optimize the formation of 46 (Scheme 14). The
manner at which the ylide was generated was the first area explored. NaH and NaHMDS were
used as methods to generate the ylide, and it was observed that NaHMDS was more efficient
resulting in a higher reaction yield (Table 2, entry 3).

Scheme 14. Hydroboration model system conditions optimization.
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In attempt to further increase the reaction yield, gentle heating of the flask was explored.
Initially the reaction was performed at 0 οC, but this was problematic due to the freezing point of
benzene (~5.5 οC). The reaction temperature was warmed to rt, and a small increase of product
formation was observed. Finally, the reaction temperature was increased slowly to 60 οC which
resulted in a 42% yield of product 46 (Table 2, entry 5).
Table 2. Model system conditions to form 46 for hydroboration reaction.
Trial

Base

Temperature
( οC)

Yield
(%)

1
2
3
4
5

NaH
NaH
NaHMDS
NaHMDS
NaHMDS

rt
50
0 → rt
rt
60

21
4
35
37
42

The optimized conditions from the model system were applied to aldehyde 8. A large
increase in isolated yield was observed of 9% to 39%. With the formation of 47, initial attempts
to form 35 were explored. With a modified procedure from Morrill et al., the hydroboration was
attempted (Scheme 15).46 BH3·THF solution was added to 47 followed by NaOH/H2O2 and the
isolated spot was examined by NMR analysis. It was observed that the alkene was converted to
the corresponding alcohol, but the carbonyl of the N-acetyl was reduced to yield alcohol 48.
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Scheme 15. Attempted hydroboration to form aza-alcohol 35.
In conclusion, a synthetic pathway utilizing an N-alkylated aldol ring closure was explored
in pursuit to produce aza-carbacepham 1. The 4π electrocyclization was optimized with the use
of flow chemistry to form 7. Deprotection of TBDMS ether 22 with Bu4NF to form alcohol 23
was found to be low yielding. An additional method was explored with the use of NIS, but no
reaction was observed. The small amount of 23 was continued on to make aza-carbacephen 25.
With the general pathway determined, initial steps to form p-fluorophenyl aza-carbacepham 2 were
completed. The synthetic pathway can then be applied to make the respective p-methoxyphenyl
aza-carbapenam 3 and m-fluorophenyl aza-carbapenam 4. Synthesis of aza-carbapenem 33 was
explored by enol-ether followed by acidic conversion to alcohol 35, which was found to be
unsuccessful. A different pathway utilized hydroboration of 47 to form the unexpected product
48. Once a large library of aza-β-lactam derivatives have been synthesized, the inhibition ability
against β-lactamase will be tested. Positive results could influence the redesign of second
generation aza-β-lactam structures.
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-Chapter 2-IntroductionMethicillin was introduced to the market in 1959 as a new method for treatment of bacterial
infections caused by penicillin-resistant Staphylococcus aureus.18 Unfortunately, isolates were
identified in the United Kingdom that had acquired resistance to methicillin in 1961.18 MRSA
isolates were later observed in European countries, Japan, Australia, and the United States.18
MRSA has become a growing problem in hospitals due to the pathogen’s ability to protect itself
against many members of the β-lactam antibiotic family.48 The resistance was brought on by the
development of the methicillin resistance gene (mecA), which encodes the methicillin-resistant
PBP2a to have a low binding affinity for the antibiotic.18 Glycopeptide antibiotics, such as
vancomycin, have been successfully used to treat various MRSA strains.

Unfortunately,

Staphylococcus aureus strains have begun to build resistance to vancomycin. Isolation of
vancomycin-intermediate, and most recently vancomycin-resistant Staphylococcus aureus
(VRSA) carrying the vanA gene have brought on the need for new treatment options. A new class
of antibiotics, oxazolidinones, are synthetic drugs that are active against a large spectrum of Grampositive bacteria, including methicillin and vancomycin-resistant staphylococci, vancomycinresistant enterococci, penicillin-resistant pneumococci and anaerobes.49

In 2000 the FDA

approved an oxazolidinone, linezolid (figure 7), for treatment of complicated skin infections
caused by MRSA.49 During the subsequent years of clinical use, emergence of resistance to
linezolid has been small, but new treatment options need to be explored.
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Figure 7. Linezolid, a clinically used oxazolidinone.
The Boudreau research group at University of New Hampshire discovered that rapamycin
potentiates the activity of oxacillin against various strains of MRSA (Table 3). In the presence of
rapamycin, the minimum inhibitory concentration (MIC) of oxacillin was substantially decreased,
but how rapamycin potentiates the activity of oxacillin is unknown.
Table 3. MIC against MRSA strains with and without the presence of rapamycin.
MIC
(µg/mL)

MRSA strain

MRSA252
NRS123
NRS70

- Rapamycin
265
16
32

+ Rapamycin
256
1
8

Rapamycin was discovered in soil samples on Easter island in 1969 and it was originally
studied for its antifungal ability, until it was also found to prevent cell multiplication.50 In 1987,
rapamycin was found to also have immunosuppressant abilities, and in 1999, the FDA approved
rapamycin as an antirejection drug prescribed to kidney transplant patients.50 Further studies of
rapamycin has discovered the molecule’s good permeability across the blood-brain barrier.51
Rapamycin has been found to have a wide variety of research applications, where it has been
engineered to control gene function through rapamycin-induced transcription as well as protein
localization, protein degradation, and DNA recombination.52,53
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From extensive analysis, four chemically accessible locations have been identified for
modification of rapamycin (Figure 8). The methoxy group, denoted at position A, was found to
undergo nucleophilic substitution and β-elimination under acidic conditions.54 The hydroxyl
group at position B has been utilized due to the easy protection with silyl groups.55,56 The lactone
at position C, can be hydrolyzed and eliminated.57 The hydroxyl group at position D has been
found to be easily converted to a carbonate group and esterified.57 With the various areas for
chemical accessibility, methods such as photoaffinity labeling can be utilized to study the
interaction of rapamycin with large biomolecules.

Figure 8. The structure of rapamycin with four chemically accessible locations, denoted A-D.
Analyzing the molecular interaction between bioactive ligands and their protein targets is
an important step in drug design. Understanding how these interactions take place allows for the
discovery of new and potentially more efficient drugs.58 With the use of a photoaffinity group, a
highly reactive species is generated to induce a covalent bond between the ligand and the protein
in a nonselective manner.58 The photophore is affixed to the ligand of interest, and with the use
of select wavelengths of light, a reactive species will form a nonselective bond to the nearby
biomolecule (Scheme 16). Successful applications of photoaffinity labeling can result in the
identification of target biomolecules in crude extracts with the aid of a radioisotope-labeled probe,
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which are highly sensitive detection tags.58 An additional advantage of photoaffinity labeling is
the ability to identify the ligand binding site and labeled amino acid. Unfortunately, identification
of photolabeled compounds can be difficult due to low photoincorporation yields.59 Multiple
options are available to combat the low photoincorporation yields such as: choice and synthesis of
the photophore, irradiation conditions, and choice of tag for the identification of the biomolecule.58

Scheme 16. Schematic representation of the process of photoaffinity labeling.
Specific groups such as aryl azides, benzophenones, or aryldiazirines (Scheme 17) have
been found to be very useful due to the highly reactive species they generate. 58 The aryl azides
are photoactivated to generate a nitrene at wavelengths below 300 nm, but low wavelengths of
light have been observed to cause damage to biomolecules, while benzophenones are radiated at
350 nm to generate a reactive triplet carbonyl state.60 The ground state carbonyl compound can
be regenerated so the photoreactive group is reusable, but long photoirradiation times are required
for this labeling process.58 Aryldiazirines generate a carbene when radiated with light at 360 nm,
which rapidly forms a covalent bond to biomolecules and does not require long photoirradiation
times.58,61
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Scheme 17. Photochemical groups with generated reactive species that are commonly used in
photoaffinity labeling.
It is crucial to limit interference when the photoaffinity probe is attached to the target
molecule. The target molecule must act as normal in order to properly study the molecular
interactions. Size is a large factor in this consideration, and the aliphatic diazirine linkers have
been found to minimize the issue of interference. The benefit of the aliphatic diazirine linker is
the overall small size, which will minimize interference with protein binding, and still maintain
the short irradiation time.62 Coupling the small size of the probe with a terminal alkyne as the
reporter, the cross-linked protein probe complex can be used for various biochemical analysis,
such as pull-down assays and LC-MS/MS, for the identification of the protein target.62 Since the
manner that rapamycin potentiates the activity of oxacillin to inhibit various strains of MRSA is
not understood, the molecular interactions can be studied by attaching an aliphatic diazirine linker
to rapamycin then examining the interaction.
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-Results and discussionThe mechanism of interaction will be studied by attaching an aliphatic diazirine linker to
rapamycin. Li et al. explored multiple small aliphatic diazirine linkers that could be used as
photoaffinity linkers.62 With the use of the diazirine linker 49, the mechanism of interaction with
oxacillin and MRSA can be studied. The hydroxyl group on the cyclohexane ring, Figure 8
position D, is the location the linker is predicted to be installed to form rapa-linker 50.63

Figure 9. Aliphatic diazirine linker 49 and respective rapa-linker 50.
Diazirine linker 49 was prepared following the synthetic pathway from Li et al. (Scheme
18).62 The synthesis started with the alkylation of ethyl acetoacetate to form 52, which was
followed by the protection of the ketone with ethylene glycol to form 53.62,64 The ester was
reduced with LiAlH4 to give the respective alcohol 54, which was deprotected with ptoluenesulfonic acid to give ketone 55.62 The formation of the diazirine ring was a multiple step
process that began with heating to reflux the ketone in anhydrous ammonia followed by the
addition of hydroxylamine-O-sulfonic acid to form the intermediate diaziridine. With the use of
an iodine solution, the diaziridine ring was oxidized to form corresponding diazirine 56, which
was followed by a halogenation to form iodo-diazirine 49.62
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Scheme 18. Synthesis of linker 49 that will be used to alkylate rapamycin.
With the synthesis of linker 49 complete, alkylation attempts of rapamycin were examined.
Rodrik-Outmezguine et al. studied the functionalization of rapamycin, and modifying the research
with linker 49, initial attempts to alkylate rapamycin were performed (Scheme 19).63

Scheme 19. Alkylation of rapamycin to form respective rapa-linker 50.
The alkylation reaction of rapamycin was monitored by TLC over time, and a new spot
formation was observed. The new spot was isolated, then examined by NMR. Unfortunately, the
data from the resulting spectra was unclear and difficult to determine if the rapa-linker 50 was
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truly formed. Calculations performed with NMR prediction software showed similarities when
compared to the 13C NMR of the isolated product, but the data was inconclusive due to the small
amount of the sample isolated. In order to fully characterize the product, more would need to be
synthesized.
The synthesis of diazirine linker 49 was successfully completed. Initial alkylation attempts
of rapamycin have yielded inconclusive results. Future direction of the project would explore
other alkylation techniques to attach the linker to rapamycin. With the formation of rapa-linker
50, the interaction with oxacillin and MRSA can be examined. The rapamycin-protein complex
can be isolated from the solution using a pull-down assay, followed by MS/MS analysis to
determine the structure of the respective protein.
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-Chapter 3I. Reagents and Solutions
All reagents and solvents employed were purchased from Acros Organics Ltd. (Hampton,
NH), Alfa-Aesar Chemicals. (Haverhill, MA), MilliporeSigma Chemical Company (St. Louis,
MO), Oakwood Products, Inc. (Estill, SC), or TCI American Chemicals. (Portland, OR) unless
specifically stated.
All reagents and solvents were of American Chemical Society (ACS) grade and were used
without further purification unless otherwise stated. All reactions were performed under a positive
pressure of nitrogen using oven or flame-dried glassware. All organic solvents when stated dry
were prepared by addition of dried over molecular sieves prior to use. For the removal of solvent,
in vacuo refers to evaporation under reduced pressure below 40 οC using a rotary evaporator
followed by evacuation (< 0.1 mm Hg) to a constant sample mass. Saturated solutions of NH4Cl,
NaHCO3, HCl, and NaOH refer to aqueous solutions. Brine refers to a saturated solution of NaCl.

II. Purification Techniques
All reactions and fractions obtained from column chromatography were monitored by thinlayer chromatography (TLC) using glass-backed plates (1.5 x 5 cm) pre-coated with silica gel
containing a UV fluorescent indicator. Compounds were visualized by exposing the plates to UV
light.
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III. Instrumentation of Compound Characterization
Nuclear magnetic resonance (NMR, 500 MHz) spectra were obtained on a Varian Mercury
400, 500 MHz spectrometers. 1H NMR chemical shifts are reported in parts per million (PPM)
relative to tetramethylsilane as the internal standard relative to the solvent of CDCl3 (δ 7.26) and
coupling constant values are given in [Hz]. The following abbreviations are given for spin
multiplicity: s = singlet, d = doublet, t = triplet, m = multiplet, dt = doublet of triplets, ddd =
doublets of doublets of doublets, td = triplet of doublets, qd = quartet of doublets. Additional
assignments were made using homonuclear correlation spectroscopy (g-COSY), heteronuclear
single quantum coherence spectroscopy (gHSQC) and heteronuclear multiple bond correlation
spectroscopy (gHMBC). All literature compounds had 1H NMR spectrum consistent with the
assigned structures.

IV. Experimental procedures and Data
1,2-Dihydro-N-phenyl-4,6-dimethylpyrimidin-2-one (6)
This known compound was prepared according to the procedure from
Muthuraman et al.30 Phenyl urea (5.45 g, 40.00 mmol) was dissolved in 95%
EtOH (50 mL) with conc. hydrochloric acid (10 mL) and stirred at room temperature for 5 min.
Acetyl acetone (4.81 g, 48.00 mmol) was added to the solution and stirred at reflux for 3 h. The
reaction mixture was cooled in an ice/water bath and the resulting solid was isolated by vacuum
filtration and washed with cold EtOH (3 x 30 mL). The white solid was dissolved in water (40
mL) and then brought to a pH of 8-10 with a sodium hydroxide solution (3.5 M, 5 mL). The
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solution was extracted with CHCl3 (3 x 50 mL), and the combined organic layers were dried with
MgSO4 then concentrated in vacuo to yield a white solid (3.6423 g, 46%): 1H NMR (CDCl3, 500
MHz) δ 7.55 – 7.21 (m, 5H, ArH), 6.20 (d, J = 0.8 Hz, 1H, C=CH), 2.42 (s, 3H, CH3), 1.99 (d, J
= 0.8 Hz, 3H, CH3).
3-Phenyl-4,6-dimethyl-2-oxo-1,3-diazabicyclo(2.2.0)hex-5-ene (7)
This known compound was prepared according to the procedure of Chandrakala
et al.26 Pyrimidinone 6 (1.20 g, 6.00 mmol) was suspended in benzene (350 mL)
and stirred at room temperature for 16 h. The solution was partitioned into 5 equal
portions and placed into quartz test tubes then irradiated with light (300 nm) for 3 h. The test tubes
were combined, and the solution concentrated in vacuo. The sample was purified by column
chromatography (SiO2, 20 % EtOAc/hexanes) to yield a yellow solid (0.3227 g, 27%): 1H NMR
(CDCl3, 500 MHz) δ 7.43 – 7.09 (m, 5H, ArH), 6.15 (q, J = 1.7 Hz, 1H, vinyl CH), 2.13 (d, J =
1.7 Hz, 3H, CH3), 1.88 (s, 3H, CH3).

3-Phenyl-4,6-dimethyl-2-oxo-1,3-diazabicyclo(2.2.0)hex-5-ene (7)
This known compound was prepared according to a modified procedure from
Chandrakala et al.26 Pyrimidinone 6 (1.00 g, 4.90 mmol) was suspended in
benzene (300 mL) and stirred for 16 h. The solution was passed through photoflow-reactor (50 mL BD glass syringe, 0.080 mL/min, 300 nm) and the solution exited into a
collection flask with benzene (~50 mL). The combined solution was concentrated in vacuo, and
purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield a yellow solid (0.6224
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g, 62%): 1H NMR (CDCl3, 500 MHz) δ 7.43 – 7.09 (m, 5H, ArH), 6.15 (q, J = 1.7 Hz, 1H, vinyl
CH), 2.13 (d, J = 1.7 Hz, 3H, CH3), 1.88 (s, 3H, CH3).

1-Phenyl-3-acetyl-4-formyl-4-methyl-1,3-diazetidin-2-one (8)
This known compound was prepared according to the procedure from Chandrakala
et al.26 Alkene 7 (0.55 g, 2.70 mmol) was dissolved in CH2Cl2 (120 mL) and
cooled to -78 οC. A steady stream of ozone was bubbled through the solution at
-78 οC until blue color persisted. O2 was bubbled through the solution until the solution became
colorless then was slowly warmed to rt. The mixture was cooled to 0 οC, then dimethyl sulfide
(1.00 mL, 0.85 g, 13.60 mmol) was added dropwise and the reaction mixture was warmed to rt
then stirred for 2 h. The reaction mixture was concentrated in vacuo, then purified by column
chromatography (SiO2, 20 % EtOAc/hexanes) to yield faint yellow solid (0.3785 g, 60%): 1H NMR
(CDCl3, 500 MHz) δ 9.45 (d, J = 0.5 Hz, 1H, CHO), 7.38– 7.12 (m, 5H, ArH), 2.48 (s, 3H,
COCH3), 1.95 (d, J = 0.5 Hz, 3H, CH3).

(4-Ethoxy-4-oxobutyl)triphenylphosphonium bromide (9)
This known compound was prepared according to the procedure from Luo et
al.35 Triphenylphosphine (3.76 g, 14.34 mmol) was dissolved in dry toluene
(20 mL) and stirred at rt for 5 min. Ethyl-4-bromobutyrate (1.47 mL, 2.00 g, 10.25 mmol) was
added dropwise to reaction flask and heated to 125 οC for 16 h. The reaction flask was cooled to
rt then Ch2Cl2 (10 mL) was added, followed by Et2O (~80 mL) until white precipitate formation
stopped. The solid was isolated by vacuum filtration and washed with Et2O (~100 mL) and dried
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to yield pure white solid (3.1498 g, 81%): 1H NMR (CDCl3, 400 MHz) δ 7.94 – 7.68 (m, 15H,
ArH), 4.15 – 4.08 (m, 4H, OCH2 and PCH2), 2.92 (td, J = 6.5, 1.4 Hz, 2H), 1.98 – 1.89 (m, 2H,
CH2), 1.25 (t, J = 7.1 Hz, 3H, CH2CH3).

(Z)-Ethyl 5-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)pent-4-enoate (10)
This compound was prepared according to a modified procedure from Luo
et al.35 Phosphonium Bromide salt 9 (0.82 g, 1.80 mmol) was suspended in
dry THF (10 mL) and cooled to -78 οC. NaHMDS solution (1 M in THF,
2.25 mL, 2.25 mmol) was added to reaction flask and stirred for 5 min at -78 οC. Aldehyde 8 (0.35
g, 1.50 mmol) in THF (5 mL) was added dropwise to the reaction flask, then allowed to warm up
to rt and stir for 16 h. The reaction mixture was diluted with EtOAc (10 mL) followed by water
(15 mL). The resulting layers were separated, and the aqueous layer was extracted with EtOAc (3
x 15 mL). The combined organic layers were dried with MgSO4 and then concentrated in vacuo.
The sample was purified by column chromatography (SiO2, 10 % EtOAc/hexanes) to yield yellow
oil (0.0770 g, 16%): 1H NMR (CDCl3, 500 MHz,) δ 7.39 – 7.07 (m, 5H, ArH), 5.78 (dt, J = 11.9,
7.2 Hz, 1H, vinyl CH), 5.67 (dt, J = 11.9, 1.9 Hz, 1H, vinyl CH), 4.09 (qd, J = 7.1, 2.1 Hz, 2H,
OCH2), 2.58 – 2.50 (m, 1H), 2.44 – 2.40 (m, 4H, 2 x CH2), 2.32 – 2.25 (m, 2H, CH2), 2.03 (s, 3H,
CH3), 1.23 (t, J = 7.1 Hz, 3H, CH2CH3); 13C NMR (CDCl3, 126 MHz) δ 172.31, 165.31, 154.12,
146.20, 137.82, 129.42, 124.96, 123.71, 115.93, 80.86, 60.51, 33.47, 24.16, 23.06, 22.89, 14.17;
HRMS (ES+) calcd for C18H24N2O4Na 355.1628 found 355.1634 [MNa]+.
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Ethyl 5-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)pentanone (11)
This compound was prepared according to a modified procedure from
Chandrakala et al.26 Ester 10 (0.08 g, 0.23 mmol) was dissolved in EtOAc
(10 mL) and flushed with N2 for 5 min. 10 % Pd/C (0.03 g) was added to
reaction flask and flushed with N2 for additional 5 min. H2 was bubbled through the solution for
10 min, then the mixture was stirred under H2 environment for 4 h. The reaction mixture was
filtered through a celite pad, then washed with EtOAc (25 mL). The filtrate was concentrated in
vacuo which afforded a colorless oil (0.0809 g, 99%) with no further purification: 1H NMR
(CDCl3, 500 MHz) δ 7.38 – 7.09 (m, 5H, ArH), 4.08 (q, J = 7.1 Hz, 2H, OCH2), 2.51 – 2.43 (m,
1H), 2.41 (s, 3H, COCH3), 2.27 – 2.20 (m, 2H, CH2), 1.91 (s, 3H, CH3), 1.66 – 1.58 (m, 2H, CH2),
1.21 (t, J = 7.1 Hz, 3H, CH2CH3); 13C NMR (CDCl3, 126 MHz) δ 173.17, 166.23, 153.95, 146.10,
129.59, 123.75, 116.04, 82.57, 60.29, 34.23, 33.97, 24.30, 22.95, 22.17, 18.62, 14.17; HRMS
(ES+) calcd for C18H22N2O4Na 353.1474 found 353.1477 [MNa]+.

4-(Hydroxymethyl)-4-methyl-1-phenyl-1,3-diazetidin-2-one (16)
This known compound was prepared according to a procedure from Chandrakala
et al.26 LiAlH4 (0.02 g, 0.50 mmol) was suspended in Et2O (8 mL) and cooled
to 0 οC. Aldehyde 8 (0.03 g, 0.12 mmol) in Et2O (3 mL) was added dropwise to
reaction flask and stirred for 1 h at 0 οC. The reaction mixture was quenched with NaOH (1 M, 1
mL) followed by water (2 mL) and the resulting solution was filtered through a celite pad. The
filtrate was extracted with Et2O (3 x 10 mL), and the combined organic layers were dried with
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MgSO4 then concentrated in vacuo. The sample was purified by column chromatography (SiO2,
50 % EtOAc/hexanes) to yield faint yellow oil (0.0184 g, 80%): 1H NMR (CDCl3, 500 MHz,) δ
7.35 – 7.07 (m, 5H, ArH), 5.02 (s, 1H, NH), 4.03 – 3.87 (m, 2H, OCH2), 1.75 (s, 3H, CH3).

(E)-Ethyl 3-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)acrylate (18)
This known compound was prepared according to the procedure from
Chandrakala et al.26 (Carbethoxymethyl)triphenylphosphonium bromide
salt (0.85 g, 1.98 mmol) was suspended in dry benzene (9 mL) and stirred
at rt for 5 min. NaH (60% in mineral oil, 0.8 g, 2.1 mmol) was added to the suspension and stirred
for 5 min. Aldehyde 8 (0.23 g, 0.99 mmol) in dry benzene (6 mL) was added dropwise to reaction
flask and stirred for 16 h at rt. The reaction mixture was diluted with water (12 mL) and the
resulting solution was separated, and the aqueous layer was extracted with Et2O (3 x 10 mL). The
combined organic layers were dried with MgSO4 and concentrated in vacuo. The sample was
purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield faint yellow oil (0.2375
g, 79%): 1H NMR (CDCl3, 500 MHz,) δ 7.35-7.12 (m, 5H, ArH), 7.07 (d, J = 15.9 Hz, 1H, vinyl
CH), 6.33 (d, J = 15.9 Hz, 1H, vinyl CH), 5.31 (s, 1H, NH), 4.23 (qd, J = 7.2, 0.8 Hz, 2H, OCH2),
2.41 (s, 2H, COCH3), 2.07 (s, 3H, CH3), 1.29 (dt, J = 20.6, 7.2 Hz, 3H, CH2CH3).

Ethyl 3-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)propanate (19)
This known compound was prepared according to the procedure from
Chandrakala et al.26 Trans ester 18 (0.24 g, 0.79 mmol) was dissolved in
EtOAc (30 mL) and flushed with N2 for 5 min. 10 % Pd/C (0.06 g) was
39

added to the reaction flask and then flushed with N2 for additional 5 min. H2 was bubbled through
solution for 10 min, then the mixture was stirred under H2 environment for 4 h. The reaction
mixture was filtered through a celite pad and washed with EtOAc (25 mL). The solution was
concentrated in vacuo to yield colorless oil (0.2745 g, 99%) with no further purification: 1H NMR
(CDCl3, 500 MHz) δ 7.37 –7.08 (m, 5H, ArH), 4.01 (q, J = 7.2 Hz, 2H, OCH2), 2.77 (ddd, J =
15.4, 9.0, 6.5 Hz, 1H, CH2), 2.48 (ddd, J = 15.4, 8.4, 7.0 Hz, 1H, CH2), 2.40 (s, 3H, COCH3), 2.34
(ddd, J = 8.8, 6.6, 3.0 Hz, 2H, CH2), 1.92 (s, 3H, CH3), 1.18 (t, J = 7.2 Hz, 3H, CH2CH3).

4-(3-Hydroxypropyl)-4-methyl-1-phenyl-1,3-diazetidin-2-one (20)
This known compound was prepared according to the procedure from
Chandrakala et al.26 LiAlH4 (0.02 g, 0.45 mmol) was suspended in Et2O (20
mL) and cooled to 0 οC. Ester 19 (0.14 g, 0.45 mmol) in Et2O (2 mL) was
added dropwise to the reaction flask and stirred for 1 h at -10 οC. The reaction mixture was
quenched with NaOH solution (1 M, 1 mL) followed by water (5 mL), and the resulting mixture
was filtered through a celite pad. The aqueous layer was extracted with Et2O (3 x 10 mL) and the
combined organic layers were dried with MgSO4 then concentrated in vacuo. The sample was
purified by column chromatography (SiO2, 80 % EtOAc/hexanes) to yield colorless oil (0.0458 g,
49%): 1H NMR (CDCl3, 500 MHz) δ 7.35 –7.04 (m, 5H, ArH), 5.13 (s, 1H, NH), 3.69 (dt, J =
10.7, 6.5 Hz, 2H, OCH2), 2.14 (ddd, J = 8.3, 6.5, 1.3 Hz, 2H, CH2), 1.80 (dt, J = 7.2, 1.6 Hz, 1H,
CH2), 1.78 (s, 3H, CH3), 1.60 – 1.59 (m, 1H, CH2).
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4-(3-((tert-butyldimethylsilyl)oxy)propyl)-4-methyl-1-phenyl-1,3-diazetidin-2-one (21)
This known compound was prepared from a modified procedure from
Chandrakala et al.26 Alcohol 20 (0.06 g, 0.26 mmol) was dissolved in
CH2Cl2 (3 mL) and cooled to 0 οC. Imidazole (0.18 g, 2.60 mmol) was
added to the reaction flask, followed by DMAP (0.002 g, 0.02 mmol) and the resulting solution
was stirred at 0 οC for 5 min. To the reaction flask, tert-butyldimethylsilyl chloride (0.20 g, 1.30
mmol) was added and the mixture was stirred for 1 h at 0 οC. The reaction was diluted with water
(3 mL), and the resulting layers were separated. The aqueous layer was extracted with CH2Cl2 (3
x 5 mL). The combined organic layers were dried with MgSO4 and concentrated in vacuo. The
sample was purified by column chromatography (SiO2, 40 % EtOAc/hexanes) to yield colorless
oil (0.0985 g, 99%): 1H NMR (CDCl3, 500 MHz) δ 7.34 – 7.03 (m, 5H, ArH), 5.14 – 5.13 (s, 1H,
NH), 3.66 – 3.61 (m, 2H, SiOCH2), 2.10 (dd, J = 8.2, 7.2 Hz, 2H, CH2), 1.86 – 1.77 (m, 1H, CH2),
1.75 (s, 3H, CH3), 1.59 – 1.55 (m, 1H, CH2), 0.91 (d, J = 17.3 Hz, 9H, SiC(CH3)), 0.12 (s, 3H,
SiCH3), 0.05 (s, 3H, SiCH3).

Ethyl 2-(2-(3-((tert-butyldimethylsilyl)oxy)propyl)-2-methyl-4-oxo-3-phenyl-1,3-diazetidin1-yl) acetate (22)
This known compound was prepared according to the procedure from
Chandrakala et al.26 NaH (60% in mineral oil, 0.06 g, 1.56 mmol) was
suspended in dry THF (5 mL) and cooled to 0 οC. TBDMS ether 21
(0.13 g, 0.39 mmol) in THF (6 mL) was added dropwise to reaction flask and stirred at 0 οC for 10
min. Ethyl bromoacetate (0.22 mL, 0.33 g, 1.95 mmol) added dropwise, then the reaction flask
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was warm to rt and stirred for 2 h. The reaction mixture was diluted with water (6 mL) and the
resulting layers separated. The aqueous layer was extracted with EtOAc (3 x 5 mL), and the
combined organic layers were dried with MgSO4 then concentrated in vacuo. The sample was
purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield colorless oil (0.2077 g,
99%): 1H NMR (CDCl3, 500 MHz) δ 7.32 –7.00 (m, 5H, ArH), 4.22 (q, J = 7.2 Hz, 2H, OCH2),
4.01 (d, J = 5.8 Hz, 2H, NCH2), 3.58 (t, J = 6.0 Hz, 2H, SiOCH2), 2.15 – 2.02 (m, 2H, CH2), 1.72
(s, 3H, CH3), 1.70 – 1.60 (m, 2H, CH2), 1.31 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.87 (s, 9H, SiC(CH3)),
0.01 (s, 3H, SiCH3), -0.01 (s, 3H, SiCH3).

Ethyl 2-(2-(3-hydroxypropyl)-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-1-yl) acetate (23)
This known compound was prepared according to the procedure from
Chandrakala et al.26 N-alkylated TBDMS ether 22 (0.02 g, 0.04 mmol) was
dissolved in dry THF (1 mL) and cooled to 0 οC. Tetrabutylammonium
fluoride (1 M in THF, 0.09 mL, 0.09 mmol) was added dropwise to reaction flask and stirred for
1 h at 0 οC. The reaction mixture was diluted with brine (3 mL) and the resulting layers separated.
The aqueous layer was extracted with EtOAc (3 x 5 mL), and the combined organic layers were
dried with MgSO4 then concentrated in vacuo.

The sample was purified by column

chromatography (SiO2, 80 % EtOAc/hexanes) to yield colorless oil (0.0082 g, 62%): 1H NMR
(CDCl3, 500 MHz) δ 7.33 – 7.01 (m, 5H, ArH), 4.23 (qd, J = 7.1, 2.3 Hz, 2H, OCH2), 4.14 (d, J =
18.3 Hz, 1H, NCH2), 3.90 (d, J = 18.3 Hz, 1H, NCH2), 3.71 – 3.55 (m, 2H, OCH2), 2.16 (ddd, J =
9.8, 7.3, 5.3 Hz, 2H, CH2), 1.87 – 1.77 (m, 1H, CH2), 1.72 (s, 3H, CH3), 1.52 – 1.42 (m, 1H, CH2),
1.31 (t, J = 7.1 Hz, 3H, OCH2CH3).
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Ethyl 2-(2-methyl-4-oxo-2-(3-oxopropyl)-3-phenyl-1,3-diazetidin-1-yl) acetate (24)
This known compound was prepared according to the procedure from
Chandrakala et al.26 Alcohol 23 (0.008 g, 0.03 mmol) was dissolved in CH2Cl2
(1 ml) and then the mixture was cooled to 0 οC. Pyridinium chlorochromate
(0.01 g, 0.06 mmol) was added, then the reaction flask was warmed to rt and stirred for 2 h. The
reaction mixture was diluted with Et2O (2 mL) then filtered through a celite pad and washed with
Et2O (3 x 2 mL). The filtrate was concentrated in vacuo to yield a colorless oil (0.0055 g, 60%)
with no further purification: 1H NMR (CDCl3, 500 MHz) δ 9.75 (s, 1H, CHO), 7.31 – 6.99 (m,
5H, ArH), 4.22 (qd, J = 7.1, 3.1 Hz, 2H, OCH2), 4.13 (d, J = 18.4 Hz, 1H, NCH2), 3.82 (d, J = 18.3
Hz, 1H, NCH2), 2.92 – 2.82 (m, 1H, CH2), 2.45 – 2.32 (m, 3H, 2 x CH2), 1.74 (s, 3H, CH3), 1.30
(t, J = 7.1 Hz, 3, OCH2CH3).

Ethyl 6-methyl-8-oxo-7-phenyl-1,7-diazabicyclo[4.2.0]oct-2-ene-2-carboxylate (25)
This known compound was prepared according to the procedure from
Chandrakala et al.26 NaH (60% in mineral oil, 0.005 g, 0.12 mmol) was
suspended in dry THF (0.5 mL) and the reaction flask was cooled to 0 οC.
Aldehyde 24 (0.006 g, 0.02 mmol) in THF (1 mL) was added dropwise to the reaction flask and
stirred for 1 h at 0 οC. The reaction mixture was diluted with Et2O (3 mL), then filtered through a
celite pad and washed with Et2O (3 x 2 mL). The collected filtrate was concentrated in vacuo, and
purified by preparative thin-layer chromatography (40 % EtOAc/hexanes) to yield azacarbacephem (0.0019 g, 39%): 1H NMR (CDCl3, 500 mHz) δ 7.34 – 7.04 (m, 5H, ArH), 6.37 –
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6.33 (m, 1H, vinyl CH), 4.45 – 4.30 (m, J = 7.1 Hz, 2H, OCH2), 2.56 – 2.49 (m, 2H, CH2), 1.79
(td, J = 12.6, 5.1 Hz, 2H, CH2), 1.67 (d, J = 0.8 Hz, 3H, CH3), 1.39 (t, J = 7.1 Hz, 3H, OCH2CH3).

(E/Z)-1-Acetyl-4-(2-methoxyvinyl)-4-methyl-3-phenyl-1-3-diazetidin-2-one (34a, 34b)
These compounds were prepared according to a modified
procedure

from

Della

et

al.45

(Methoxymethyl)triphenylphosphonium chloride (0.86 g, 2.51
mmol) was suspended in dry THF (8 mL) and the reaction flask was cooled to -78 οC. NaHMDS
(1 M in THF, 2.40 mL, 2.40 mmol) was added dropwise to the reaction flask and stirred for 5 min
at -78 οC. Aldehyde 8 (0.29 g, 1.25 mmol) in THF (4 mL) was added dropwise, then the reaction
flask allowed to warm to rt and stir for 16 h. The mixture was diluted with water (8 mL) followed
by Et2O (8 mL). The resulting layers were separated, and the aqueous layer was extracted with
Et2O (3 x 10 mL). The combined organic layers were dried with MgSO4 and concentrated in
vacuo. The sample was purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield
solid in a 4.3:1 mixture of E/Z isomers (0.0303 g, 9%): 1H NMR (CDCl3, 500 MHz) δ 7.37 – 7.09
(m, 5H, ArH), 6.90 (d, J = 12.9 Hz, 1H, vinyl CH), 5.03 (d, J = 12.9 Hz, 1H, vinyl CH), 3.61 (s,
3H, OCH3), 2.39 (s, 3H, COCH3), 2.02 (s, 3H, CH3);

C NMR (CDCl3, 126 MHz) δ 165.55,

13

153.53, 146.35, 135.82, 129.35, 123.49, 116.06, 110.00, 100.33, 56.52, 23.20, 21.28; HRMS
(ES+) calcd for C14H16N2O3Na 283.1053 found 283.1059 [MNa]+.
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Methyl-2-methyl-2-phenylpropanate (43)
This known compound was prepared according to the procedure from Bonneau et
al.47 N-Diisopropylamine (16.91 mL, 12.14 g, 120.00 mmol) and bipyridyl (0.003
g, 0.02 mmol) were dissolved in dry THF (120 mL) and the reaction flask was cooled to -78 οC.
n-BuLi (1.6 M in THF, 75 mL, 120.00 mmol) was added dropwise to reaction flask and stirred at
-78 οC for 5 min. Methyl phenylacetate (4.22 mL, 4.50 g, 30 mmol) in THF (50 mL) was added
to the reaction flask and stirred for 15 min at -78 οC. Iodomethane (9.34 mL, 21.29 g, 150.00
mmol) was added dropwise and the reaction mixture was allowed to slowly warm to rt and stir for
3 h. The mixture was diluted with water (100 mL) followed by CH2Cl2 (100 mL) and the resulting
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 80 mL), and the
combined organic layers were dried with MgSO4 and concentrated in vacuo.
In a new dry flask, additional portion of N-diisopropylamine (16.91 mL, 12.14 g, 120.00 mmol)
and bipyridyl (0.003 g, 0.02 mmol) were dissolved in dry THF (120 mL) and cooled to -78 οC.
n-BuLi (1.6 M in THF, 75 mL, 120.00 mmol) was added dropwise to reaction flask and stirred at
-78 οC for 5 min. The crude sample from before in THF (50 mL) was added dropwise to reaction
flask and stirred for 15 min at -78 οC. Iodomethane (9.34 mL, 21.29 g, 150.00 mmol) was added
dropwise and then the reaction flask was warmed to rt and stirred for 3 h. The mixture was diluted
with water (100 mL) followed by CH2Cl2 (100 mL) and resulting layers were separated. The
aqueous layer was extracted with CH2Cl2 (3 x 80 mL) and the combined organic layers were dried
with MgSO4 then concentrated in vacuo. The sample was purified by column chromatography
(SiO2, 5 % EtOAc/hexanes) to yield colorless oil (3.6706 g, 69%): 1H NMR (CDCl3, 500 MHz) δ
7.37 – 7.24 (m, 5H, ArH), 3.67 (s, 3H, OCH3), 1.61 (s, 6H, 2 x CH3).
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2-Methyl-2-phenylpropan-1-ol (44)
This known compound was prepared according to a modified procedure from
Zaysev et al.44 LiAlH4 (0.85 g, 22.40 mmol) was suspended in dry Et2O (100 mL)
and the reaction flask was cooled to 0 οC. 43 (1.00 g, 5.60 mmol) in Et2O (20 mL) was added
dropwise and the reaction flask and was stirred for 1 h at 0 οC. The reaction mixture was diluted
with water (40 mL) and filtered through a celite pad. The filtrate was extracted with Et2O (3 x 30
mL), and the combined organic layers were dried with MgSO4 then concentrated in vacuo. The
sample was purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield colorless
oil (0.7225 g, 86%): 1H NMR (CDCl3, 500 MHz) δ 7.48 – 7.20 (m, 5H, ArH), 3.64 (d, J = 6.5 Hz,
2H, OCH2), 1.36 (s, 6H, 2 x CH3).

2-Methyl-2-phenylpropanol (45)
This known compound was prepared according to a modified procedure from
Zaysev et al.44 Pyridinium chlorochromate (1.44 g, 6.66 mmol), sodium acetate
(0.08 g, 1.00 mmol), and silica (1.03 g, 16.65 mmol) were suspended in CH2Cl2 (60 mL) and
stirred at rt for 5 min. Alcohol 44 (0.50 g, 3.33 mmol) in CH2Cl2 (6 mL) was added dropwise to
reaction flask and stirred for 2 h at rt. The reaction mixture was filtered through a silica pad and
washed with CH2Cl2 (3 x 20 mL). The filtrate was concentrated in vacuo and purified by column
chromatography (SiO2, 5 % EtOAc/hexanes) to yield colorless oil (0.3251 g, 69%): 1H NMR
(CDCl3, 500 MHz) δ 9.53 (s, 1H, CHO), 7.43 – 7.26 (m, 5H, ArH), 1.49 (s, 6H, 2 x CH3).
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(2-Methylbut-3-en-2-yl)benzene (46)
This known compound was prepared according to a modified procedure from
Morrill et al.46 In the reaction flask, methyltriphenylphosphonium bromide (0.97 g,
2.70 mmol) was suspended in dry benzene (8 mL) and stirred at rt for 5 min. NaHMDS (1 M in
hexanes, 2.60 mL, 2.60 mmol) was added dropwise and the mixture stirred for 5 min at rt.
Aldehyde 45 (0.18 g, 1.23 mmol) in benzene (2 mL) was added dropwise and the reaction flask
was heated to 60 οC for 16 h. The reaction mixture was cooled to rt, then diluted with water (8
mL) and the resulting layers separated. The aqueous layer was extracted with EtOAc (3 x 10 mL),
and the combined organic layers were dried with MgSO4 then concentrated in vacuo. The sample
was purified by column chromatography (SiO2, 10 % EtOAc/hexanes) to yield colorless oil
(0.0737 g, 41%): 1H NMR (CDCl3, 500 MHz) δ 7.40 –7.19 (m, 5H, ArH), 6.06 (ddd, J = 17.3,
10.6, 0.5 Hz, 1H, vinyl CH), 5.11 – 5.00 (m, 2H, =CH2), 1.43 (d, J = 0.5 Hz, 6H, 2 x CH3).

1-Acetyl-4-methyl-3-phenyl-4-vinyl-1,3-diazetidin-2-one (47)
This compound was prepared according to a modified procedure from Morrill et
al.46 Methyltriphenylphosphonium bromide (1.67 g, 3.29 mmol) was suspended
in dry benzene (15 mL) and stirred at rt for 5 min. NaHMDS (1 M in THF, 3.10
mL, 3.10 mmol) was added dropwise and the reaction flask was stirred for 5 min at rt. Aldehyde
8 (0.38 g, 1.63 mmol) in benzene (5 mL) was added dropwise to the reaction flask and then heated
to 60 οC for 16 h. The reaction mixture was cooled to rt, then diluted with water (15 mL) and the
resulting layers separated. The aqueous layer was extracted with EtOAc (3 x 15 mL), and the
combined organic layers were dried with MgSO4 then concentrated in vacuo. The sample was
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purified by column chromatography (SiO2, 10 % EtOAc/hexanes) to yield yellow solid (0.1448 g,
39%): 1H NMR (CDCl3, 500 MHz) δ 7.37 – 7.10 (m, 5H, ArH), 6.11 (dd, J = 17.4, 10.7 Hz, 1H,
=CH2), 5.72 (d, J = 17.3 Hz, 1H, vinyl CH), 5.60 (d, J = 10.7 Hz, 1H, =CH2), 2.40 (s, 3H, COCH3),
2.03 (s, 3H, CH3); 13C NMR (CDCl3, 126 MHz) δ 165.61, 155.04, 146.24, 135.78, 134.69, 129.36,
123.68, 116.11, 79.73, 23.14, 19.56; HRMS (ES+) calcd for C13H14N2O2Na 253.1134 found
253.1129 [MNa]+.

1-Ethyl-4-(2-hydroxyethyl)-4-methyl-3-phenyl-1,3-diazetidin-2-one (48)
This compound was prepared according to a modified procedure from Morrill
et al.46 Alkene 47 (0.10 g, 0.46 mmol) in dry THF (4 mL) was cooled to 0 οC,
then borane tetrahydrofuran complex (1 M in THF, 0.92 mL, 0.92 mmol) was
added dropwise. The reaction flask was warm to rt and stirred for 1 h, then a second portion of
BH3·THF (1 M in THF, 0.50 mL, 0.50 mmol) was added and stirred for additional 30 min at rt.
The reaction mixture was cooled to 0 οC, then in a dropwise manner a NaOH solution (1 M, 4 mL)
was added which was immediately followed by the addition of H2O2 solution (30%, 4 mL) and the
reaction mixture was warmed to rt and stirred for 1 h. The reaction mixture was diluted with brine
(10 mL) and the resulting layers were separated. The aqueous layer was extracted with EtOAc (3
x 10 mL), and the combined organic layers were dried with MgSO4 and concentrated in vacuo.
The sample was purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield yellow
oil (0.0317 g, 29%): 1H NMR (CDCl3, 500 MHz) δ 7.31 –7.15 (m, 5H, ArH), 6.98 (tt, J = 7.1, 1.2
Hz, 1H, NCH2), 3.78 – 3.62 (m, 2H, OCH2), 3.36 – 3.13 (m, 2H, CH2), 2.32 – 2.13 (m, 3H), 1.66
(s, 3H, CH3), 1.25 (t, J = 7.3 Hz, 4H, NCH2CH3); 13C NMR (CDCl3, 101 MHz) δ 153.93, 137.71,
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129.34, 122.34, 115.77, 79.68, 57.90, 38.29, 35.19, 22.92, 14.91; HRMS (ES+) calcd for
C13H18N2O2Na 257.1266 found 257.1266 [MNa]+.

7-Octyne-2,4-dione (52)
This known compound was prepared according to the procedure from
Hayakawa et al.64

To the reaction flask, N-diisopropylamine (7.09 mL,

5.12 g, 50.60 mmol) was dissolved in dry THF (50 mL) and then cooled to -78 οC. n-BuLi (1.6 M
in THF, 48.7 mL, 63.25 mmol) was added dropwise and stirred at -78 oC for 5 min. Ethyl
acetoacetate (3.22 mL, 3.29 g, 25.30 mmol) in THF (20 mL) was added dropwise to the reaction
flask, then stirred at 0 oC for 30 min. Propargyl bromide (80 % in toluene, 3.10 g, 25.30 mmol)
was added in one portion to the reaction flask and stirred at 0 oC for 1 h. The reaction was quenched
with a sat. NH4Cl solution (4 mL), then diluted with water (50 mL) and Et2O (50 mL). The
resulting layers were separated, and the aqueous layer extracted with Et2O (2 x 25 mL). The
combined organic layers were washed with brine (50 mL) and dried with MgSO4, then
concentrated in vacuo.

The sample was purified by column chromatography (SiO2, 10 %

EtOAc/hexanes) to yield colorless oil (2.8212 g, 66%): 1H NMR (CDCl3, 400 MHz) δ 4.21 (q, 2H,
OCH2), 3.46 (s, 2H, CH2), 2.82 (t, 2H, CH2), 2.47 (m, 2H, CH2), 1.96 (s, 1H, CH), 1.28 (t, 3H,
OCH2CH3).

Ethyl-2-(2-(3-butynyl)-1,3-dioxolan-2-yl)acetate (53)
This known compound was prepared according to the procedure from
Hayakawa et al.64 Alkyne 52 (2.17 g, 12.90 mmol) was dissolved in benzene
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(40 mL) and stirred at rt for 5 min. Ethylene glycol (2.17 mL, 2.41 g, 38.70 mmol) was added to
the reaction flask followed by p-toluenesulfonic acid (0.25 g, 1.30 mmol) and the mixture was
heated to reflux with a dean-stark trap for 16 h. The reaction was cooled to rt, then poured over a
sat. NaHCO3 solution (40 mL) and ice. The resulting layers were separated, and the aqueous layer
was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (20
mL), dried with MgSO4 then concentrated in vacuo. The sample was purified by column
chromatography (SiO2, 20 % EtOAc/hexanes) to yield faint yellow oil (2.1101 g, 77%): 1H NMR
(CDCl3, 400 MHz,) δ 4.21 (q, 2H, OCH2), 4.01 (s, 4H, OCH2CH2O), 3.46 (s,2H, CH2), 2.82 (t,
2H, CH2), 2.47 (m, 2H, CH2), 1.96 (s, 1H, CH), 1.28 (t, 3H, OCH2 CH3).

2-(3-butynyl)-2-(2-hydroxyethyl)-1,3-dioxolane (54)
This known compound was prepared according to the procedure from
Hayakawa et al.64 LiAlH4 (0.38 g, 10.10 mmol) was suspended in dry THF
(35 mL) and cooled to -78 oC. Protected ester 53 (2.13 g 10.10 mmol) in THF (5 mL) was added
dropwise to the reaction flask. The reaction mixture was warm to rt and stirred for 3 h. The
reaction mixture was quenched with a 15% NaOH solution (10 mL), then filtered through a celite
plug. The filtrate was extracted with EtOAc (3 x 20 mL) and the combined organic layers were
dried with MgSO4 then concentrated in vacuo.

The sample was purified by column

chromatography (SiO2, 50 % EtOAc/hexanes) to yield a colorless oil (1.4512 g, 86%): 1H NMR
(CDCl3, 400 MHz,) δ 4.01 (m, 4H, OCH2CH2O), 3.76 (q, 2H, CH2), 2.66 (t, 1H, CH2), 2.28 (m,
2H, CH2), 1.96 (m, 5H, 2 x CH2 and CH).
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1-Hydroxyhept-6-yn-3-one (55)
This known compound was prepared according to the procedure from
Hayakawa et al.64 Alcohol 54 (1.36g, 8.00 mmol) was dissolved in acetone
(25 mL) and stirred at rt for 5 min. p-Toluenesulfonic acid (0.38 g, 2.00 mmol) was added and the
reaction flask was stirred at rt for 2 h. The reaction mixture was poured over a sat. NaHCO3
solution (20 mL) and ice, and the resulting layers were separated. The aqueous layer was extracted
with Et2O (3 x 20 mL), and the combined organic layers were washed with brine (20 mL), dried
with MgSO4, then concentrated in vacuo. The sample was purified by column chromatography
(SiO2, 80 % EtOAc/hexanes) to yield a colorless oil (0.6834 g, 67%): 1H NMR (CDCl3, 400 MHz,)
δ 3.87 (t, 2H, OCH2), 2.71 (t, 4H, 2 x CH2), 2.48 (m, 2H, CH2), 2.38 (br, 1H, OH), 1.97 (t, 1H,
CH).

2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)ethanol (56)
This known compound was prepared according to the procedure form
Hayakawa et al.64 With the use of a cold finger trap, anhydrous ammonia (35
mL) was condensed into reaction flask containing ketone 55 (4.43 g, 35.00 mmol). The reaction
flask was then heated to 40 oC and stirred for 5 h maintaining cold finger trap at -78 οC.
Hydroxylamine-O-sulfonic acid (4.55 g, 40.25 mmol) in methanol (35 mL) was added dropwise
to the reaction flask, then continued to be heated at 40 oC for 1 h. The cold finger trap was slowly
warm to rt and the ammonia was allowed to evaporate overnight. The resulting white solid was
filtered through a silica plug and washed with methanol (3 x 25 mL), then condensed in vacuo.
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The mixture was dissolved in CH2Cl2 (17 mL) and triethylamine (6.13 mL, 4.45 g, 43.98 mmol)
was added to the reaction flask, and stirred for 30 min at rt. An iodine solution (8 g, 50.4 mmol in
18 mL CH2Cl2) was added dropwise to the reaction flask until an orange/brown color persisted,
and the resulting solution was concentrated in vacuo. The sample was purified excluding light by
column chromatography (SiO2, 80 % CH2Cl2/hexanes) to yield a faint yellow oil (2.02 g, 43%):
1

H NMR (CDCl3, 400 MHz,) δ 3.51 (t, 2H, ICH2), 2.07 (m, 3H, CH2 and CH), 1.70 (m, 5H, 2 x

CH2 and OH).

3-(but-3-yn-1-yl)-3-(2-iodoethyl)-3H-diazirine (49)
This known compound was prepared according to the procedure from
Hayakawa et al.64 Iodine (1.11 g, 4.40 mmol), triphenylphosphine (1.05 g, 4.00
mmol), and imidazole (0.74 g, 10.90 mmol) were dissolved in CH2Cl2 (20 mL) and the reaction
flask was cooled to 0 oC. Excluding light, diazirine 56 (0.50 g, 3.60 mmol) in CH2Cl2 (4 mL) was
slowly added to reaction flask and stirred for 4 h at 0 oC. The reaction mixture was quenched with
a sat. Na2S2O3 solution (20 mL) and the resulting layers were separated. The aqueous layer was
extracted with EtOAc (3 x 25 mL), and the combined organic layers were washed with brine (30
mL), dried with MgSO4, then concentrated in vacuo. The sample was purified excluding light by
column chromatography (SiO2, 8 % EtOAc/hexanes) to yield a yellow oil (0.3822 g, 42%): 1H
NMR (CDCl3, 400 MHz,) δ 2.89 (t, 2H, CH2), 2.12 (t, 2H, CH2), 2.01 (m, 3H, CH2 and CH), 1.69
(t, 2H, CH2).
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